| 1 |
33657325 | An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. | 2021 Mar 18 |
1 |
| 2 |
34900242 | Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound. | 2021 Dec |
1 |
| 3 |
30152697 | isoDGR-Peptides for Integrin Targeting: Is the Time Up for RGD? | 2018 Sep 13 |
1 |
| 4 |
26956095 | Vitronectin-Based, Biomimetic Encapsulating Hydrogel Scaffolds Support Adipogenesis of Adipose Stem Cells. | 2016 Apr |
1 |
| 5 |
24154564 | Optimized multimodal nanoplatforms for targeting α(v)β3 integrins. | 2013 Dec 7 |
1 |
| 6 |
21881228 | Fibrinolytic activation promoted by the cyclopentapeptide malformin: involvement of cytoskeletal reorganization. | 2011 |
1 |
| 7 |
19882657 | Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. | 2010 Jan |
2 |
| 8 |
18658131 | Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. | 2008 Oct 17 |
2 |
| 9 |
17355965 | Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. | 2007 May 4 |
2 |
| 10 |
15722127 | Cell adhesive PET membranes by surface grafting of RGD peptidomimetics. | 2005 Aug |
1 |
| 11 |
15843372 | Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. | 2005 Jun 24 |
1 |
| 12 |
20641262 | 68Ga-1,4,7-Triazacyclononane-1,4-7-triacetic acid-Glu-[c(Arg-Gly-Asp-D-Tyr-Lys)]2 | 2004 |
1 |
| 13 |
20641300 | 111In-TA138 | 2004 |
1 |
| 14 |
20641458 | 68Ga-1,4,7-Triazacyclononane-1,4-7-triacetic acid-Glu-[Gly-Gly-Gly-c(Arg-Gly-Asp-D-Phe-Lys)]2 | 2004 |
1 |
| 15 |
20641531 | Cyclo(Arg-Gly-Asp-d-Tyr-Lys)-Cy5.5 | 2004 |
1 |
| 16 |
20641584 | 4-[18F]Fluorobenzoyl-ε-Lys1-c(KRGDe)MDDPGRNPHhCitGPAT | 2004 |
1 |
| 17 |
20641599 | Cyclo(-Arg-Gly-Asp-d-Phe-Lys(([18F]Fluoropropionyl)galacto-amino acid)-) | 2004 |
1 |
| 18 |
20641803 | 99mTc-Ethylenediaminediacetic acid/hydrazinonicotinic acid-cyclo(Arg-Gly-Asp-D-Try-Lys) | 2004 |
1 |
| 19 |
20641917 | 68Ga-1,4,7-Triazacyclononane-1,4-7-triacetic acid-Glu-[15-amino-4,7,10,13-tetraoxapentadecanoic acid-c(Arg-Gly-Asp-D-Phe-Lys)]2 | 2004 |
1 |
| 20 |
20641959 | Microbubbles-echistatin | 2004 |
1 |
| 21 |
20642000 | 99mTc-Diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol | 2004 |
1 |
| 22 |
21061495 | 64Cu-Labeled 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-ylamino)methyl)benzoic acid (AmBaSar) conjugated to cyclic arginine-glycine-aspartic acid (RGD) peptide | 2004 |
1 |
| 23 |
21204315 | Microbubbles conjugated with knottin 2.5D | 2004 |
1 |
| 24 |
21249762 | 64Cu-1,4,7,10-Tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid-Lys(Cy5.5)-Gly-Gly-Tyr-knottin 2.5D | 2004 |
1 |
| 25 |
22319801 | Cyclo(Cys-Arg-Gly-Asp-Cys)-Gly-Lys-Cy5.5 | 2004 |
1 |
| 26 |
22457887 | 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glu[cyclo(Lys-Arg-Gly-Asp-d-Phe)]-cyclo(Lys-Arg-Gly-Asp-d-Phe)}-{PEG4-Glu[cyclo(Lys-Arg-Gly-Asp-d-Phe)]-cyclo(Lys-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,710,13-tetraoxapentadecanoic acid) | 2004 |
1 |
| 27 |
22457888 | 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glu[cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)]-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)}-{PEG4-Glu[cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)]-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,7,10,13-tetraoxapentadecanoic acid) | 2004 |
1 |
| 28 |
22457890 | 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glu[cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)]-cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)}-{PEG4-Glu[cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)]-cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,7,10,13-tetraoxapentadecanoic acid) | 2004 |
1 |
| 29 |
22649803 | 123I-c(RGDfK)-human serum albumin-tissue inhibitor of matrix metalloproteinase 2 fusion protein | 2004 |
1 |
| 30 |
22649804 | 68Ga-1,4,7-Triazacyclononane-1,4,7-triacetic acid-c(RGDfK)-human serum albumin-tissue inhibitor of matrix metalloproteinase 2 fusion protein | 2004 |
1 |
| 31 |
23115806 | 68Ga-1,4,7-Triazacyclononane-1,4,7-triacetic acid-c(RGDyK)-S-S-CPLHSpT | 2004 |
1 |
| 32 |
23285494 | Indocyanine green derivative 02-Glu-c(RGDyK)2 | 2004 |
1 |
| 33 |
23720861 | Gadolinium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-icosahedral closo-borane12 scaffold conjugated with Glu-{Glu-[cyclo(Arg-Gly-Asp-d-Phe-Lys)]2}2 | 2004 |
1 |
| 34 |
12009947 | In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. | 2002 May-Jun |
1 |
| 35 |
10037735 | Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional. | 1999 Mar 5 |
1 |
| 36 |
9765407 | Interactions of soluble recombinant integrin alphav beta5 with human adenoviruses. | 1998 Nov |
1 |
| 37 |
9030577 | The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1. | 1997 Feb 21 |
1 |
| 38 |
9120775 | Interaction of thrombin-activated platelets with extracellular matrices (fibronectin and vitronectin): comparison of the activity of Arg-Gly-Asp-containing venom peptides and monoclonal antibodies against glycoprotein IIb/IIIa complex. | 1997 Jan |
1 |
| 39 |
9202057 | Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. | 1997 Jul 1 |
1 |
| 40 |
9242985 | Evidence for a specific interaction of vitronectin with arginine: effects of reducing agents on the expression of functional domains and immunoepitopes. | 1997 Apr |
6 |
| 41 |
8550313 | Adhesion of human trabecular meshwork cells to extracellular matrix proteins. Roles and distribution of integrin receptors. | 1996 Jan |
1 |
| 42 |
8648190 | Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins. | 1996 Mar |
1 |
| 43 |
8747525 | A mimetic of the RGDF-peptide [arginine-glycine-aspartic acid-phenylalanine] blocks aggregation and flow-induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans. | 1996 Jan 1 |
1 |
| 44 |
7513610 | A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins alpha v beta 3, alpha v beta 5, and alpha v beta 6. | 1994 Apr 15 |
1 |
| 45 |
8036014 | Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. | 1994 Aug |
1 |
| 46 |
7683462 | The cell attachment and spreading activity of vitronectin is dependent on the Arg-Gly-Asp sequence. Analysis by construction of RGD and domain deletion mutants. | 1993 Apr 30 |
2 |
| 47 |
7683657 | Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion. | 1993 May 5 |
2 |
| 48 |
21043846 | Vitronectin inhibits blood platelet aggregation. | 1993 |
1 |
| 49 |
1284063 | Sperm surface proteins after capacitation. Expression of vitronectin on the spermatozoan head and laminin on the sperm tail. | 1992 Nov-Dec |
1 |
| 50 |
1323869 | [The glycoprotein IIb/IIIa complex of the platelets. An activation-dependent integrin]. | 1992 Feb |
2 |